NEW YORK, NY / ACCESSWIRE / July 27, 2017 / U.S. markets continued to reach record highs Wednesday as upbeat earnings from bellwether companies, such as Boeing Co. and AT&T Inc., continue to boost investor optimism. Additionally, the Federal Reserve announced it would leave interest rates unchanged and indicated it would soon begin to reduce its $4.5 trillion balance sheet. The S&P 500 Index is currently trading at approximately 18 times earnings estimates for the next 12 months, which is above the long-term average of 15 times earnings estimates, according to Reuters. The Dow Jones Industrial Average gained 0.45 percent to close at 21,711.01, while the S&P 500 Index inched up 0.03 percent to close at 2,477.83. The Nasdaq Composite Index rose 0.16 percent to close at 6,422.75.

"The market is right to be driven by earnings and so far we've had enough upside surprises. Because it has been the most hated bull market, there is still room to grow," said Kim Forrest, senior portfolio manager at Fort Pitt Capital.

RDI Initiates Coverage on:

Biogen Inc.
https://ub.rdinvesting.com/news/?ticker=BIIB

Pluristem Therapeutics Inc.
https://ub.rdinvesting.com/news/?ticker=PSTI

Biogen Inc.'s stock moved 4.47% higher Wednesday, to close the day at $295.61. The stock recorded a trading volume of 3,014,605 shares, which was above its three months average volume of 1,551,160 shares. In the last year Biogen Inc.'s shares have traded in a range of 244.28 - 307.76. The share price has gained 21.01% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $272.62 is below its 200-day moving average of $273.66. Shares of the company are trading at a Price to Earnings ratio of 18.51. Shares of Biogen Inc. have gained approximately 4.24 percent year-to-date.

Access RDI's Biogen Research Report at:
https://ub.rdinvesting.com/news/?ticker=BIIB

On Wednesday, shares in Pluristem Therapeutics Inc. recorded a trading volume of 470,325 shares, which was above the three months average volume of 167,457 shares. The stock ended the day 3.39% higher at 1.22. The share price has gained 17.31% from its 52 week low with a 52 week trading range of 1.04 - 1.85.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $1.28 is below its 200-day moving average of $1.29. Shares of Pluristem Therapeutics have fallen approximately 14.69 percent year-to-date.

Access RDI's Pluristem Therapeutics Research Report at:
https://ub.rdinvesting.com/news/?ticker=PSTI

Our Actionable Research on Biogen Inc. (NASDAQ: BIIB) and Pluristem Therapeutics Inc. (NASDAQ: PSTI) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer or a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute

SOURCE: RDInvesting.com